Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
NCT05116683Phase 2Terminated
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATX101 in dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS). Primary endpoint: Progression Free Rate at 12 weeks. Started Jan 2022; status: terminated.
02
Drugs
ATX101
03
Conditions
dedifferentiated liposarcoma (DDL)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT05116683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116683.